Biological/Vaccine: BNT162b2 3mcg for COVID-19

We found no reliable single pathogen for causing coronaviruses in the outbreak. This suggests that the disease is due to multiple contributing factors. Recent findings suggests that exposure to viruses other than SARS-CoV2 may also trigger the disease. Further research into this is warranted.

In the early and middle stages of the SARS-Covvirus 2 infection, people had fewer symptoms including pain by the time of death. This suggests that the virus could be cured by timely treatment. However, in the late stage of the infection, the virus can be cured only by a precise intervention strategy.

Based on this initial evidence, COVID-19 could evolve into either a deadly coronavirus infections disease associated with severe pulmonary disease or a non-life-threatening respiratory infection with predominantly mild-to-moderate symptoms.

The current study identifies common treatments for an emerging medical condition and provides a simple to-use reference to help patients and their physicians decide what to do for themselves through online referrals.

In the United States, approximately 0.1 million new patients acquire the disease each year; with an overall estimated death rate of 2.4%, this makes the virus the second most lethal pathogen in the country (next to influenza, although influenza has a much higher fatalities ratio per 1000 infections). The epidemic is concentrated in the elderly population (those with poor health and more severe illnesses), women, and blacks. The majority of cases occur within the United States. As of April 10, 2019, 25 states and the District of Columbia have confirmed cases of the virus in persons either abroad or who visited abroad and tested positive for either a traveler's infection due to visiting a country with a confirmed case or imported infection.

In the current situation, the disease can be diagnosed by the symptoms; it does not have any laboratory parameter or imaging study. No imaging study is available in the current situation.

The mortality rate among those with COVID-19 that is estimated to be over 20% is comparable with rates in influenza outbreaks of that magnitude. This finding is reassuring, as it confirms the safety of the current countermeasures for the present epidemic. The shortening of the recovery period and the potential future consequences of serious complications are key considerations; however, until research on treatment strategies is ongoing, these findings should be interpreted cautiously.

At 1 year the efficacy of Bnt162b2 3mcg was 74%. At year 2 its efficacy increased to 90% The overall vaccine (Bnt162b2 10microg)/antigen (Bnm1 24ng) is the safest and most effective treatment as of now for this disease, based on available evidence.

Average age of the first person in the general population to get diagnosed with Covid-19 was 49.3 years (95% CI: 46.4-54.7). Average age of the first person in the healthcare worker population to get diagnosed with Covid-19 was 55.4 years (95% CI: 47.1-63.1). Age distribution analysis revealed that Covid-19 had a skewed age distribution with more people aged 20 years and younger being infected and more people aged 55 years and older being infected. Given the age-distribution in the general population, we believe that those who are between 45 and 55 years old may have a lower risk of being infected with the virus.

There is evidence that familial transmission of the virus is possible, and is probably rare due to a lack of evidence of the mutant strains in the rest of the population and low infectiousness of the virus in familial cases. The overall prevalence of the mutant strains in the United States was 1.9%. This suggests that no evidence of a transmission mechanism beyond ordinary infection with the virus exists. It is not clear how frequent the mutant strain is in the domestic pig population, as is the case in wildlife populations, how it spread into the human population, and what the transmission cycle is.

This is the first study showing bnt162b2 to be more efficient than a placebo treatment in reducing clinical symptoms of H1N1-infected patients, with a duration of 5.5 days of bnt162b2, compared to 4 days of placebo (P =.026). These data could be used for more effective treatment of H1N1 flu in general in primary health care settings, especially when access and availability issues can make access to antiviral treatment difficult or when the treatment is not recommended as first-line therapy of H1N1 infection.